Cargando…

CS15-01 Can We Prevent Hepatocellular Carcinoma in Chronic Hepatitis B?

Detalles Bibliográficos
Autor principal:	Chan, Henry L.Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society for Infectious Diseases. Published by Elsevier Ltd. 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128178/ http://dx.doi.org/10.1016/S1201-9712(09)60302-7

Ejemplares similares

CS15-03 Prevention of HCC Related to Viral Hepatitis
por: Cheng, Jun
Publicado: (2009)

Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?
por: Russo, Francesco Paolo, et al.
Publicado: (2022)

Mouse models of hepatocarcinogenesis: What can we learn for the prevention of human hepatocellular carcinoma?
por: Vucur, Mihael, et al.
Publicado: (2010)

CS15-04 The Role of Polo-like Kinase 1 as a Therapeutic Target in Hepatocellular Carcinoma
por: Lim, Seng-Gee
Publicado: (2009)

Can we add another C to the 6Cs: C for Clever?
por: Ali, Parveen
Publicado: (2019)

CS15-02 Current Japanese Strategies for Preventing HCC Development
por: Ueno, Yoshiyuki
Publicado: (2009)

A Simple Noninvasive Index Can Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
por: Zhu, Lihui, et al.
Publicado: (2017)

Can we prevent breast cancer?
por: Baum, M., et al.
Publicado: (1991)

Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma
por: Kim, Soo Ryang, et al.
Publicado: (2023)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Can indication of hepatic resection for hepatocellular carcinoma patients be expanded?
por: Kubota, Keiichi
Publicado: (2023)

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
por: Wenger, Justin B., et al.
Publicado: (2011)

Viral Hepatitis and Hepatocellular Carcinoma Prevention Strategy in Japan
por: Oda, Toshitsugu
Publicado: (1999)

Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma
por: Alqahtani, Saleh A., et al.
Publicado: (2021)

Hepatocellular Carcinoma Prevention in the Era of Hepatitis C Elimination
por: Lazarus, Jeffrey V., et al.
Publicado: (2023)

Genetic Susceptibility to Hepatocellular Carcinoma in Patients with Chronic Hepatitis Virus Infection
por: Yang, Tsai-Hsuan, et al.
Publicado: (2023)

Hepatitis B prevention: Can we learn from the response to HIV/AIDS?
por: Kretzschmar, Mirjam E. E., et al.
Publicado: (2020)

Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?
por: Chao, Wu-Po, et al.
Publicado: (2023)

Prevention of Hepatocellular Carcinoma Development Associated with Chronic Hepatitis by Anti-Fas Ligand Antibody Therapy
por: Nakamoto, Yasunari, et al.
Publicado: (2002)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
por: Lee, Sung Won, et al.
Publicado: (2021)

Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
por: Kim, Jong Man
Publicado: (2021)

Identification of serum CCL15 in hepatocellular carcinoma
por: Li, Y, et al.
Publicado: (2013)

CS15.1 CMV in transplant recipients
por: Tan, B.-H.
Publicado: (2011)

Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma
por: Ailioaie, Laura Marinela, et al.
Publicado: (2020)

Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update
por: Lok, James, et al.
Publicado: (2021)

Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C
por: Tanaka, H, et al.
Publicado: (2008)

From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?
por: Sessa, Anna, et al.
Publicado: (2021)

CS-01 Rapid Recurrence and Anaplastic Transformation of a Pilocytic Astrocytoma in an Elderly Patient
por: Tanaka, Toshihide, et al.
Publicado: (2020)

Fatal outcome of SARS in a patient with reactivation of chronic hepatitis B
por: Hui, Alex Y., et al.
Publicado: (2003)

Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma
por: Zhang, Xinhe, et al.
Publicado: (2021)

Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
por: Meringer, Hadar, et al.
Publicado: (2019)

Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis
por: Thiele, Maja, et al.
Publicado: (2013)

Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure
por: Lee, I-Cheng, et al.
Publicado: (2017)

Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2020)

Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
por: Choi, HeeKyoung, et al.
Publicado: (2021)

Transition of Antibody to Hepatitis C Virus from Chronic Hepatitis to Hepatocellular Carcinoma
por: Kiyosawa, Kendo, et al.
Publicado: (1990)

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults
por: Ockenhouse, Christian F., et al.
Publicado: (2015)

Anxiety in adolescence. Can we prevent it?
por: Llorca, Anna, et al.
Publicado: (2017)

Can we prevent childhood Leukaemia?
por: Greaves, Mel, et al.
Publicado: (2021)

CS-01 GIANT CELL TUMOR IN THE SKULL BASE BONE TREATED WITH ANTI-RANKL INHIBITOR
por: Kajiwara, Yoshinori, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_taj0gi7hu5sk39cv3d2tsl6bsi